# Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study

> **NCT00145444** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 100 (—)

## Conditions studied

- Schizophrenia
- Psychotic Disorders

## Interventions

- **DRUG:** olanzapine
- **DRUG:** ziprasidone

## Key facts

- **NCT ID:** NCT00145444
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 100 (—)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00145444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00145444, "Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00145444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*